Zymeworks (NASDAQ: ZYME) has recently received a number of price target changes and ratings updates:
- 11/13/2026 – Zymeworks had its price target raised by Citizens Jmp from $32.00 to $39.00. They now have a “market outperform” rating on the stock.
- 11/11/2026 – Zymeworks had its price target raised by Citigroup from $39.00 to $44.00. They now have a “buy” rating on the stock.
- 11/10/2026 – Zymeworks had its price target raised by TD Cowen from $34.00 to $39.00. They now have a “buy” rating on the stock.
- 11/10/2026 – Zymeworks had its price target raised by Truist Financial from $35.00 to $36.00. They now have a “buy” rating on the stock.
- 11/10/2026 – Zymeworks had its price target raised by HC Wainwright from $55.00 to $56.00. They now have a “buy” rating on the stock.
- 10/27/2026 – Zymeworks had its price target raised by Truist Financial from $34.00 to $35.00. They now have a “buy” rating on the stock.
- 10/26/2026 – Zymeworks had its “market outperform” rating reaffirmed by Citigroup.
- 10/23/2026 – Zymeworks had its “buy” rating reaffirmed by Jefferies Financial Group. They now have a $52.00 price target on the stock.
- 10/15/2026 – Zymeworks had its “sell (d-)” rating reaffirmed by Weiss Ratings.
- 10/7/2026 – Zymeworks had its price target raised by Truist Financial from $32.00 to $34.00. They now have a “buy” rating on the stock.
- 9/29/2026 – Zymeworks had its “buy” rating reaffirmed by Citigroup. They now have a $39.00 price target on the stock, up from $38.00.
- 9/29/2026 – Zymeworks is now covered by TD Cowen. They set a “buy” rating and a $34.00 price target on the stock.
Zymeworks Trading Down 2.3%
Shares of Zymeworks stock opened at $25.84 on Wednesday. The firm’s 50 day moving average is $27.22 and its 200 day moving average is $25.52. The firm has a market capitalization of $1.78 billion, a PE ratio of 49.69 and a beta of 1.32. Zymeworks Inc. has a 1 year low of $21.52 and a 1 year high of $31.97.
Zymeworks (NASDAQ:ZYME – Get Free Report) last issued its quarterly earnings data on Monday, November 9th. The company reported $2.28 EPS for the quarter, beating the consensus estimate of $2.27 by $0.01. Zymeworks had a net margin of 16.10% and a return on equity of 22.23%. The business had revenue of $512.92 million during the quarter, compared to the consensus estimate of $227.40 million. During the same quarter in the prior year, the firm earned ($0.26) EPS. The firm’s revenue was up 828.7% compared to the same quarter last year. As a group, research analysts anticipate that Zymeworks Inc. will post 1.31 earnings per share for the current year.
Insider Buying and Selling at Zymeworks
Zymeworks Inc. is a biotechnology company headquartered in Vancouver, Canada, that develops engineered medicines, with a focus on treatments for cancer and other serious diseases. Its antibody-engineering technologies are designed to create therapies that can engage multiple biological targets or modify immune responses. The company’s lead program is zanidatamab, a HER2-targeted bispecific antibody. In the United States, it is marketed by partner Jazz Pharmaceuticals as Ziihera for certain adults with previously treated, unresectable or metastatic biliary tract cancer.
Read More
- Five stocks we like better than Zymeworks
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Zymeworks Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks Inc and related companies with MarketBeat.com's FREE daily email newsletter.
